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Minocycline as a treatment for traumatic brain injury-induced impulsive and attentional deficits 
Kristen M. Pechacek 
Traumatic brain injury (TBI) impacts millions worldwide and can cause lasting psychiatric 
symptoms. Chronic neuroinflammation is a characteristic of post-injury pathology and is 
positively associated with psychiatric conditions such as ADHD and bipolar disorder. Therefore, 
the current study sought to treat TBI-induced impulsivity and inattention using minocycline, an 
antibiotic with anti-inflammatory properties. Rats were trained on the five-choice serial reaction 
time task (5CSRT), a measure of motor impulsivity and attention. After behavior was stable on 
the 5CSRT, rats received either a bilateral frontal TBI or sham procedure. Minocycline was 
given at either 1 h post-injury or beginning at 8 weeks after injury. The minocycline treatment 
consisted of 45mg/kg via intraperitoneal injections given every 12 h for 5 days. Behavioral 
testing on the 5CSRT began again after one week of recovery and continued for 12 weeks post-
injury, then rats were transcardially perfused. Impulsivity and inattention were both substantially 
increased following TBI. Minocycline at both the early (1 h post-injury) and late (8 weeks post-
injury) time points failed to affect TBI-induced impulsivity and inattention. TBI rats had 
increased lesion volume, but minocycline did not attenuate the lesion size. Additionally, 
microglia levels measured by IBA-1+ cells did not differ between TBI and sham rats, and 
minocycline did not differentially change the number of microglia in TBI rats. Based on the 
results of this study, minocycline does not appear to be an effective treatment for post-injury 
psychiatric-like symptoms. 
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Minocycline as a treatment for traumatic brain injury-induced impulsive and attentional deficits 
 Traumatic brain injury (TBI) is defined as damage to the brain that is caused by an 
external force (Ahmed et al., 2017). It is estimated that nearly 69 million people worldwide 
sustain a TBI each year (Dewan et al., 2018), and approximately 1-2% of the United States 
population are living with TBI-related disability (Thurman, Alverson, Dunn, Guerrero, & 
Sniezek, 1999). Brain injury often results in long-term neurological and psychiatric symptoms, 
such as impulsivity and attention deficits (Ozga, Povroznik, Engler-Chiurazzi, & Vonder Haar, 
2018; Reeves & Panguluri, 2011). Despite the number of TBI survivors, there are no FDA-
approved pharmacological treatments available. However, symptom-specific treatments may be 
available to manage TBI-induced cognitive impairments. Neuroinflammation can persist years 
after injury (Ramlackhansingh et al., 2011), and is associated with impulsive symptoms after TBI 
(Vonder Haar et al., 2016). Thus, chronic neuroinflammation after TBI may be a contributing 
factor to injury and cognitive impairments, as well as a potential avenue for treatment. One such 
potential therapeutic, minocycline, is a tetracycline antibiotic that has anti-inflammatory 
properties (Yong et al., 2004). Additionally, the study of TBI in humans is complicated by the 
heterogeneity of injuries, which hampers comparisons of drug efficacy and potency. Conversely, 
preclinical models provide control by limiting both genetic variance and heterogeneity of injury. 
The current study used a rat model of TBI to examine minocycline as a treatment for TBI-
induced impulsivity and attentional deficits. Specifically, this study looked at minocycline in two 
ways: (1) prevent injury-induced cognitive impairments with early treatment, and (2) recover 
injury-induced dysfunction with a late intervention. This design allowed for the determination of 
neuroinflammation as causal to persistent psychiatric deficits or to the development of such 
impairments. 
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Preclinical Models of Brain Injury 
One of the most common models of traumatic brain injury is the controlled cortical 
impact (CCI). Initially developed by Lighthall (1988) to induce damage in ferrets, it was later 
adapted to be used in rodents (Dixon, Clifton, Lighthall, Yaghmai, & Hayes, 1991). The CCI 
produces focal injuries using an impactor tip that is controlled either pneumatically or 
electromagnetically. These focal injuries allow for a high level of precision compared to injuries 
humans typically sustain by having various adjustable parameters such as velocity, depth, and 
size and shape of the tip. Having reliable injuries also leads to a greater amount of 
reproducibility. The CCI model is ideal for studying long-term outcomes associated with TBI 
because it has a high survival rate and progressive pathological changes (Osier & Dixon, 2016). 
Evidence from the Vonder Haar Lab shows consistent cognitive impairments and tissue damage 
up to 12 weeks post-injury (Martens et al., 2019; Shaver et al., 2019). Along with this, other 
studies find reliable long-term impairments on the Morris Water Maze (MWM) following CCI 
injury in rats (Cheng et al., 2012; Xiong et al., 2012). In contrast, other injury models such as 
fluid percussion fail to report steady chronic impairments on the MWM (Hamm, Pike, Temple, 
O'Dell, & Lyeth, 1995; Shultz et al., 2012). The bilateral frontal TBI is used to induce focal 
damage in the prefrontal cortex (Hoffman, Fülöp, & Stein, 1994). In the current study, a severe 
bilateral frontal CCI was used to induce TBI.  
Cognitive Impairment after Traumatic Brain Injury 
Impaired impulse control is a common complaint of TBI patients and can manifest as 
verbal or physical actions that result from an inability to inhibit a response (McAllister, 2008). 
Motor impulsivity often displays as impulsive aggression (quick, aggressive response to minimal 
stimulus) and is correlated with criminal behaviors after TBI (Alderman, 2003; Dyer, Bell, 
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McCann, & Rauch, 2006). Another consequence of poor impulse control in clinical TBI 
populations is hypersexuality or inappropriate sexual behavior (Simpson, Sabaz, & Daher, 2013). 
Both aggressive behavior and unfitting sexual behavior caused by injury-induced impulsivity can 
reduce quality of life for individuals after brain injury.   
Attention deficits are another commonly-reported symptom after TBI (Reeves & 
Panguluri, 2011). Inattention can disrupt daily function, and attention impairments after TBI 
must be addressed. There is strong evidence supporting that TBI increases impulsivity and 
inattention, yet, no treatments to recover function have been discovered; therefore, there is a 
strong need to develop effective treatments.  
Impulsivity  
Impulsive behavior is defined as an action that has the potential for a short-term gain, but 
at the cost of long-term benefits (Ozga et al., 2018; Winstanley, Eagle, & Robbins, 2006). As a 
complex cognitive construct, it is hard to define and measure impulsivity in a single term; 
therefore, it can be broken down into two major categories, motor impulsivity, and choice 
impulsivity. Motor impulsivity is response disinhibition or acting without thinking. Choice 
impulsivity is often referred to as discounting and the inability to value delayed rewards (Ozga et 
al., 2018; Winstanley et al., 2006).  
Several tasks are used to study motor impulsivity in humans and include: stop-signal, 
continuous performance, and go/no-go tasks. In the stop-signal and go/no-go tasks, participants 
respond rapidly to a “go” stimulus, but an occasional “stop” stimulus signals that responding 
should be inhibited. Damage to the right inferior frontal gyrus impairs performance on the stop-
signal task (Aron, Fletcher, Bullmore, Sahakian, & Robbins, 2003). Patients with brain injuries 
had lower levels of response inhibition, and their performance significantly dropped when 
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distracted with an emotion-driven distractor (Rochat, Beni, Annoni, Vuadens, & Van der Linden, 
2013). The continuous performance task measures motor impulsivity, sustained, and selective 
attention by having constantly changing stimuli with a target stimulus that signals to respond or 
to inhibit responding. Both continuous performance task and go/no-go are similar response-
inhibitory tasks that find consistent TBI-related impulsivity deficits in clinical studies (Chen et 
al., 2012; Duncan, Kosmidis, & Mirsky, 2005; Stephens et al., 2017). However, while substantial 
clinical data supports a relationship between TBI and impulsivity, animal models must be used to 
investigate the nuances of this connection to understand the underlying mechanisms.  
Typical measures for motor impulsivity in rodents include: Go/no-go, stop-signal task, 
differential reinforcement of low-rate behavior (DRL), and the five-choice serial reaction time 
task (5CSRT). These tasks often resemble measurements of motor impulsivity in humans. For 
instance, go/no-go, and stop-signal tasks use the similar design of having “go” cues that animals 
learn to respond to and then “stop” cues to which responding must be inhibited (Winstanley et 
al., 2006). The DRL is a free-operant task that requires a complete stop in responding for a 
duration of time to receive reinforcement (Ferster & Skinner, 1957). Several preclinical studies 
in rodents report TBI-related motor impulsivity deficits on the go/no-go, stop-signal, and DRL 
(Hehar, Yeates, Kolb, Esser, & Mychasiuk, 2015; Lindner et al., 1998; Mychasiuk, Hehar, & 
Esser, 2015). The 5CSRT simultaneously measures attention, impulsivity, and motivation 
(Robbins, 2002). Bilateral frontal TBI increased impulsivity and inattention measured by the 
5CSRT (Martens et al., 2019; Vonder Haar et al., 2016). Although impulsivity and attention can 
be studied separately, it is crucial that they are studied together, because the difference between 
impulsivity and inattention can be subjective. For example, inattention could lead to an 
impulsive response, whereas impulsivity could bring on poor attention (Winstanley et al., 2006). 
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Impulsivity and attention are connected topics and studying these concepts together is best, 
especially when assessing for treatments because it yields stronger translation into clinical 
populations.  
Attention  
Attention is broadly defined as the action of processing environmental stimuli (Robbins, 
2002). Attention has multiple facets but can be broken down into three parts: sustained, divided, 
or selective attention. Sustained attention is the ability to maintain attention for long durations, 
whereas divided attention is the ability to process multiple contingencies from sensory inputs and 
respond accordingly. Selective attention is the capacity to respond to one stimulus in the 
presence of several different stimuli (Mathias & Wheaton, 2007; Robbins, 2002). Both sustained 
and divided attention are impaired in clinical TBI populations (Dockree et al., 2004; Tramontana, 
Cowan, Zald, Prokop, & Guillamondegui, 2014; Robertson & Schmitter-Edgecombe, 2017). 
Sustained attention deficits make complex tasks difficult and challenge the individual to get 
through a full day. Subsequently, this could lead to a decrease in performance at work or school 
and in turn, reduce the quality of life. Consequently, it is vital to develop treatments that can 
recover TBI-induced attention dysfunction.  
There are several tests that measure attention, and since attention is a multifaceted 
concept, interpretations of the same test may vary. Therefore, it is important to clearly define the 
type of attention being studied and to use the proper test to assess that variable. Sustained 
attention is measured using tasks across longer durations. Tests such as the Sequence Sustained 
Attention Task, Continuous Performance Task, or Attention Network Test measure sustained 
attention and all show decreased performance after brain injury (Dockree et al., 2004; 
Tramontana et al., 2014; Lawton & Huang, 2019). Divided attention is measured with tasks that 
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have multiple contingencies (e.g., visual stimulus and audio tones) and attending to both is 
reinforced. After severe TBI in humans, there is a decrease in divided attention (Robertson & 
Schmitter-Edgecombe, 2017; Tramontana et al., 2014). Despite this clinical evidence, preclinical 
models need to address mechanisms behind TBI-related attention dysfunction to find effective 
and targeted treatments. 
           In preclinical measures of attention, the 5CSRT is predominately used and animals with 
moderate-to-severe injuries display impaired attention (Martens et al., 2019; Vonder Haar et al., 
2016). The 5CSRT was adapted from the Continuous Performance Task, a neuropsychological 
test used to diagnose ADHD (Carli, Robbins, Evenden, & Everitt, 1983). This task 
simultaneously measures impulsivity, attention, and motivation, and each aspect can be 
disassociated from one another. Specifically, the 5CSRT measures motor impulsivity (premature 
responding) and sustained attention (attending across the whole visual field) both of which are 
impaired after injury. Bilateral frontal CCIs show consistent deficits in both attention and 
impulsivity using the 5CSRT (Martens et al., 2019; Vonder Haar et al., 2016). Because of these 
advantages, for the proposed work, the 5CSRT was used.  
Inflammation after Traumatic Brain Injury 
Damage after TBI comes in two forms: primary and secondary injury. Primary injury is 
damage from the initial insult and occurs at the time of the blow; these injuries consist of 
neuronal cell death, axonal shearing, cerebral contusion, and hemorrhage (Stein, Brailowsky, & 
Will, 1995). Secondary injuries are the indirect results of TBI that start to develop minutes after 
the initial hit to the head. These secondary injuries are from biochemical, metabolic, and cellular 
changes from the primary injury and include oxidative stress, blood-brain barrier disruptions, cell 
death, mitochondrial dysfunction, excitotoxicity, and neuroinflammation (Loane & Faden, 2010). 
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Although primary injuries can be substantial, secondary injuries such as neuroinflammation, 
propagate damage and persist years post-injury (Loane & Faden, 2010; Ramlackhansingh et al., 
2011). Reducing secondary damage after TBI may decrease chances of lasting behavioral effects. 
The inflammatory response begins several hours after injury and can last years (Loane & 
Kumar, 2016). In TBI populations, increased pro-inflammatory markers have been reported up to 
17 years post-injury (Ramlackhansingh et al., 2011). The neuroinflammatory response after 
injury is complex and involves immune cells from the bloodstream that enter through the 
disrupted blood-brain barrier, and immune-like cells in the central nervous system (Loane & 
Kumar, 2016; Simon et al., 2017). Damage-associated molecular patterns (DAMPS) are proteins, 
nucleic acids, or other molecules that are present in cells before the injury and are released in 
response to cellular damage. In contrast, apoptosis, the controlled destruction of cells, does not 
result in the release of DAMPS (Loane & Kumar 2016). These DAMPS activate immune 
responders such as microglia and astrocytes in the central nervous system, and macrophages and 
neutrophils from peripheral tissues (Wofford, Loane, & Cullen, 2019). Once these immune cells 
accumulate around the injury, they start to clear debris via phagocytosis; however, as they clean, 
they also release toxic substances such as reactive oxygen species, chemokines, and cytokines 
that can augment cellular damage and prolong neuroinflammation (Donat, Scott, Gentleman, & 
Sastre, 2017; Loane & Kumar, 2016). Ischemic strokes have a similar response in that microglia 
are the first responders to injury then infiltrating peripheral immune cells follow (Ma et al., 
2017). In the context of ischemic stroke, microglia cells become activated within minutes of the 
ischemic event and can produce inflammatory mediators such as nitric oxide synthase, nitric 
oxide, and pro- and anti-inflammatory cytokines (Ma et al., 2017).  
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Microglia play a significant role in the neuroinflammatory response after brain injury 
(Donat et al., 2017; Loane & Kumar, 2016). Microglia exist along a spectrum of pro-
inflammatory and anti-inflammatory processes but can be dichotomized to an M1-like (pro-
inflammatory) and M2-like (anti-inflammatory) phenotype (Kumar, Alvarez-Croda, Stoica, 
Faden, & Loane, 2016). In the M1-like state, microglia typically exhibit pro-inflammatory 
processes, and they will signal and produce pro-inflammatory cytokines such as tumor necrosis 
factor-alpha (TNF-α), interleukin (IL) 1-beta, and IL-6. The M1-like state is related to chronic 
neuroinflammation, oxidative stress, and neuronal destruction through phagocytosis (Xu et al., 
2017). Conversely, microglia in the M2-like state exhibit anti-inflammatory characteristics. M2-
like microglia typically increase neurotrophic factors, clear cell debris without changing 
morphology, and release anti-inflammatory cytokines such as IL-4 and IL-10 (Song & Suk, 
2017). After TBI, microglia exist in both M1-like and M2-like states. However, the M2-like 
levels peak within five days post-injury and then the M1-like state dominates, promoting a 
prolonged pro-inflammatory response (Jin, Ishii, Bai, Itokazu, & Yamashita, 2012). In ischemic 
stroke, microglia have a similar response to injury and exist in both the pro- and anti-
inflammatory states.  Initially after ischemic stroke, microglia will exhibit M1-like 
characteristics such as increased levels of cluster of differentiation (CD) CD11b, CD16, CD32, 
and CD86 but not starting until day 3 after injury (Hu et al., 2012). M2-like microglia after 
stroke are associated with increases in expression of IL-10 and TGF-β. These anti-inflammatory 
microglia levels begin to increase within the first day after injury, but peak by day 5 post-stroke 
(Hu et al., 2012). Due to these dynamic processes of microglia, it is essential to consider the 
time-dependent nature of manipulating microglia after brain injury.  
MINOCYCLINE & TBI   9 
 
Neuroinflammation is a common form of secondary injury and can last years after the 
initial injury (Ramlackhansingh et al., 2011). Cognitive symptoms such as impulsivity and 
attention deficits have been reported as chronic effects after brain injury (Dockree et al., 2004; 
Rochat et al., 2013). Psychiatric disorders that have characteristics of impulsiveness and 
inattention, such as Attention-Deficit/ Hyperactivity Disorder have been linked with increased 
inflammatory cytokine markers (Mitchell & Goldstein, 2014). Specifically, increased IL-6 was 
associated with impulsivity, and inattention was associated with increased IL-13 (Oades, Myint, 
Dauvermann, Schimmelmann, & Schwarz, 2010). The long-term cognitive deficits seen in TBI 
may be exacerbated by prolonged neuroinflammation; thus, treatments that target the 
inflammatory response should be explored.  
Minocycline 
Minocycline is a broad-spectrum antibiotic that is typically used to treat acne and 
sexually transmitted infections (Garrido-Mesa, Zarzuelo, & Gálvez, 2013). Minocycline is a 
lipophilic molecule and can easily pass through the blood-brain barrier, making it available for 
CNS interventions (Garrido-Mesa et al., 2013; Yong et al., 2004). It has neuroprotective 
properties related to microglia deactivation (Henry et al., 2008; Yong et al., 2004). In the central 
nervous system, minocycline can reduce neuroinflammation, decrease cell-death, and promote 
neurotrophic factors (Yong et al., 2004). Minocycline can inhibit microglia, both directly and 
indirectly. Direct inhibition of microglia by minocycline occurs through reducing the expression 
of toll-like receptor (TLR) 2 and TLR4 on microglia cells (Henry et al., 2008; Zhao, Zhang, & Li 
2015). These TLRs recognize DAMPs or other foreign substances and activate an innate immune 
response; specifically, TRL4 activation leads to the synthesis of pro-inflammatory cytokines and 
chemokines (Vaure & Liu, 2014). Minocycline reduces pro-inflammatory signalers such as 
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caspase I, nitric oxide synthase, and genes for IL-6, TNF-α, IFN-γ, and IL-1β, thus, decreasing 
the inflammatory response (Henry et al., 2008; O’connor et al., 2009). In vitro, minocycline 
reduced the pro-inflammatory effects of LPS by decreasing the expression of p38 and MMP9 
and reducing IL-6 and IL-1β production by microglia (Piotrowska, Popiolek-Barczyk, Pavone, & 
Mika, 2017).  In vitro, astrocytes demonstrated a response like that of the microglia reducing 
expression of p39 and MMP9 as well as pro-inflammatory signals (Piotrowska et al., 2017). Due 
to astrocytic reliance of microglia post-injury neuroinflammation, microglia were the primary 
interest for this work. Therefore, I hypothesized that reducing the microglial pro-inflammatory 
response may decrease long-term dysfunction after TBI.  
In some rat models of TBI, minocycline attenuates injury-related deficits such as 
cognitive impairments, lesion size, and microglia levels. Minocycline treatment recovered spatial 
learning and memory dysfunction measured by Morris water maze and the Barnes maze 
(Kovesdi et al., 2012; Kumar, Rinwa, & Dhar, 2014; Lam et al., 2013; Sangobowale et al., 2018; 
Simon et al., 2018). Minocycline also reduced the number of microglia present and decreased 
lesion size (Adembri et al., 2014; Haber et al., 2018; Hanlon, Raghupathis, & Huh, 2017). 
However, these therapeutic effects depended on the dose. At 45 mg/kg, minocycline can reduce 
lesion size and decrease microglia after injury (Adembri et al., 2014; Haber et al., 2018; Hanlon 
et al., 2017). Similarly, at higher doses of 50 mg/kg, 60 mg/kg, and 90 mg/kg there was 
functional recovery and decreased pathology of inflammatory markers such as microglia and 
pro-inflammatory cytokines (Kovesdi et al., 2012; Kumar et al., 2014; Simon et al., 2018; 
Vonder Haar et al., 2014). At doses lower than 45 mg/kg, the effect of minocycline was more 
variable in recovering behavioral deficits or decreasing lesion size or microglia levels (Lam et 
al., 2013; Kelso, Scheff, Scheff, & Pauly, 2011; Sangobowale et al., 2018). The effectiveness of 
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the dose also depended on the severity of injury and most behavioral recovery was seen when the 
injury was moderate-to-severe. The current study used a severe injury and 45 mg/kg of 
minocycline based on the previous work reviewed above. Minocycline was an effective 
treatment starting at various time points post-injury, including: immediate, 10 min, 30 min, 1 h, 2 
h, 4 h, 6 h, 12 h, 24 h, and 15 d (Adembri et al. 2014; Haber et al., 2018; Kovesdi et al. 2012; 
Kumar et al., 2014; Lam et al. 2013; Sangobowale et al., 2018; Simon et al., 2018; Vonder Haar 
et al. 2014). We started an early round of treatment at 1 h post-injury before neuroinflammation 
fully progresses. In humans, the half-life of minocycline ranges 15- 24 h hours; however, in 
rodents, the half-life is about 2-3 h (Yong et al., 2004). Although minocycline has a short half-
life in rodents, we dosed every 12 h because this still dampened the pro-inflammatory microglial 
response after brain injury and had been effective in multiple previous studies. For a summary of 
minocycline rat studies see Table 1. 
Preclinical data is promising for the use of minocycline as a treatment for TBI, yet, 
limited clinical work has been done. Treatments of minocycline six months after moderate-to-
severe injury reduced microglial activation (Scott et al., 2018). These treatments also increased 
neurofilament light chain (a measure of active neurodegeneration) after 12 weeks of taking the 
drug, but this attenuated after 6 months of treatment (Scott et al., 2018). Another study found 
large doses of minocycline to be safe after TBI (Meythaler et al., 2019). These two clinical 
studies show minocycline as a promising potential treatment for TBI-related deficits. However, 
clinical trials often fail due to accelerated testing of novel drugs that lack proper validation. 
Thus, it is important to refine and continue preclinical studies. 
Authors Injury 
Severity 





Haber et al., 
2018 
Mild 45mg/kg 1 h post-
injury every 
24 h  
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Table 1. Minocycline in rat models of TBI, and its effects on behavior, microglia, and lesions. 
Arrows indicate increase or decrease; flat line represents no effect.   
The Current Study 
           The current work used minocycline to treat impulsivity and inattention after TBI. This 
was the first time an anti-inflammatory treatment was used to alleviate impulsivity- and 
Hanlon, Huh, & 
Raghupathi, 
2016 










Mild 45mg/kg 0 h post- 
injury every 
12 h  
  
 
(10 d)(15 d) 
 
Kovesdi et al. 
2012 
Mild 50mg/kg 4 h post-
injury every 







& Dhar, 2014 
Mild 25mg/kg 15 d post-
injury every 
24 h  
   
Kumar, Rinwa, 
& Dhar, 2014 
Mild 50mg/kg 15 d post-
injury every 









45mg/kg 30 m post-
injury then 
every 12 h  
   
Lam et al., 2013 Moderate- 
severe  
25mg/kg 24 h post-
injury every 







Moderate 22.5mg/kg 6, 12, or 24 
h then every 





















60mg/kg 2 h post- 
injury then 
Every 12 h 
for 72 h 
   
Kelso, Scheff, 
Scheff, & Pauly 
2011 
Severe 40mg/kg 24 h post-
injury every 
24 h  
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attention-related impairments. The 5CSRT was used to measure motor impulsivity and attention. 
The different treatment interventions of minocycline began at 1 h and 8 weeks post-injury. Post-
injury behavioral testing on the 5CSRT stabilized at 7 weeks post-injury; therefore, the late 
minocycline treatment began at 8 weeks after injury. The early treatment tested whether 
dysfunction could be prevented by minocycline whereas the late intervention at 8 weeks after 
injury examined if minocycline could attenuate such deficits.  I hypothesized that minocycline 
treatment would reduce motor impulsivity at the 8-week time point and prevent an increase of 
impulsivity, relative to sham levels, at the early dose. I also hypothesized that attention deficits 
would be recovered with minocycline at the 8-week time and the initial dose would prevent 
worsening relative to shams. Lastly, I hypothesized that minocycline would reduce brain 
microglia numbers, as compared to untreated rats subjected to CCI and would decrease the lesion 
size in the early dose group.   
Methods 
Subjects 
Subjects were male, Long-Evans rats (N = 35) approximately 250 - 275g, obtained from 
Charles River Laboratories. Rats were kept in Optirat cages (Animal Care Systems, Centennial, 
CO) with corncob bedding and crinkle paper. These rats were triple-housed until surgery, then 
moved to pair-housing, separated by a divider, after surgery. Environmental conditions were 
controlled, and rats were kept in an AAALAC accredited vivarium on a 12 h light/dark reverse 
cycle. Rats had free access to water and were maintained at 85 % of their free-feeding weight 
using standard chow receiving 14g of food per day. All work was approved by the West Virginia 
University Institutional Animal Care and Use Committee.     
Apparatus  
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Testing took place in 16 standard five-hole operant chambers (Med Associates, St. 
Albans, VT). The chambers were located in sound-attenuating boxes, and white noise machines 
(about 70 dB) were used to ensure background noise was minimized. The chambers had a 
stainless-steel grid floor and contain two extendable levers, five nose-poke holes with infrared 
sensors, and a food hopper. The food hopper was between the two levers, and the five nose-poke 
holes were located on the opposite side of the chamber. Above the levers and in the nose-poke 
holes were stimulus lights, and above the food hopper was a house light. The chambers were also 
equipped with a tone generator that were not used in this study. Only the five nose-poke holes 
with stimulus lights and food hopper were used in this study. Sucrose pellets (45 mg, BioServ, 
Fleming, NJ) were used as reinforcers. Custom software written in Med-PC IV controlled the 
chambers.  
Behavioral Testing – the 5-choice serial reaction time task 
The 5CSRT measures impulsivity and attention. Trials were initiated with a nose poke 
into the food hopper and a 5 s inter-trial interval (ITI) began, in which rats had to inhibit 
responding. Responses during the ITI (i.e., a premature response) were punished with a 5 s 
timeout. After the ITI, a stimulus light in one of five of the holes illuminated for 0.5 s and 
responding correctly (nose poke to illuminated hole) within the 5 s limited hold was reinforced. 
Failure to respond within the limited hold (i.e., omission) was punished with a 5 s timeout, and 
an incorrect response (i.e., nose poke to wrong hole) was punished with a 5 s timeout. Each 
session lasted for 30 minutes and had a maximum of 100 trials (see Figure 1). The main variables 
of interest included premature responses (impulsivity), correct and incorrect responses 
(attention), omissions, task efficacy index (correct/(incorrect + premature + omissions).  
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Figure 1. Diagram of 5–choice serial reaction time task; adapted from Robbins, 2002.  
Behavior Training 
Behavioral training was adapted from prior publications (Carli et al., 1983; Vonder Haar 
et al., 2016). To reduce neophobia, sucrose pellets were placed in the housing cages one day 
before behavioral training began. First, rats were habituated to the operant chambers by placing 5 
sucrose pellets into each of the five nose poke holes and 10 pellets into the food hopper. After 
consuming all of the sucrose pellets within 30 min, rats moved on to the 5-choice training 
sessions. The 5-choice training stages included 12 stages that had varying ITI, stimulus 
durations, and limited holds (LH). Stage 1 started with a 2 s ITI and 30 s stimulus duration and 
30 s LH. As the stages progressed, the ITI, stimulus durations, and LH gradually got closer to the 
full task of (5 s ITI, 0.5 s stimulus duration, and 5 s LH). A training session lasted for 30 min and 
rats moved on to the next stage after criteria for their current stage was met (e.g., 30 correct 
responses; see appendices for more details). Stability criteria was defined as a consistent number 
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of correct, incorrect, premature, and omission data for five days, which took approximately 65 
sessions.  
Surgery  
Rats were pair-matched based on premature and attention baseline data on the 5CSRT 
then assigned to receive a TBI (n = 23) or sham injury (n = 12). Rats received a severe bilateral 
frontal controlled cortical impact TBI (Hoffman et al., 1994). First, rats were anesthetized with 
isoflurane (5% induction, 2-4% maintenance) in 0.5L/min oxygen. Rats were placed on a 
stereotaxic frame, local analgesic (bupivacaine, 0.1 mL of 0.25% solution) was administered at 
the incision site, and general analgesic given subcutaneously (ketoprofen, 5mg/kg). Next, the 
incision site was sterilized, a midline incision performed, and retractors were placed. A 6 mm 
diameter circular craniotomy was completed at 3 mm anterior to bregma, centered on the 
midline. A Leica Impact One device (Leica Biosystems, Buffalo Grove, IL) was used to induce a 
bilateral TBI with a consistent depth (-2.5 mm), velocity (3 m/s), and dwell (500 ms). Sterile 
gauze was used to stop bleeding after the impact, and then the incision site was sutured. Triple 
antibiotic ointment was put on the incision site to prevent infection. Sham surgeries were 
identical to TBI but excluded the impact. 
Treatment/Treatment Groups 
Minocycline hydrochloride (Cayman Chemical, Ann Arbor, MI) 45 mg/kg given in a 12 
mg/ml solution or vehicle (saline volume matched based on body weight) was delivered via 
intraperitoneal route. One group started treatment 1 h post-injury (MINO-Early) and the other 
received drug at 8 weeks post-injury (MINO-Late). Minocycline or vehicle was administered 
twice daily every 12 h for 5 days. There were 6 groups including: Sham-VEH (n=5), Sham-
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MINO-Early (n=7), TBI-VEH (n=7), TBI-MINO-Early (n=7), TBI-MINO-Late (n=9) (see table 
2). Minocycline had no effect on behavior in the early dose (accuracy:  t(54.353) = 1.3369,  p = 
0.187; premature: t(60.307) = -1.1096, p = 0.2716). Therefore, the Sham-MINO-Early and 




Table 2. Groups.  
Behavioral Assessment 
Rats had 7 days of post-surgery recovery before they resume testing on the 5CSRT. Rats 
were tested 12 weeks post-injury, that is, 4 weeks after the late round of minocycline treatment 
concluded. 
 
Figure 2. Timeline of the study design.  
Histology  
 VEH MINO-Early MINO-Late 
Sham 5 7 -- 
TBI 7 7 9 
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Upon completion of behavioral testing (12 weeks after injury), rats were transcardially 
perfused with 0.9% phosphate buffered saline, followed by 3.7% phosphate buffered 
formaldehyde. Brains were fixed in 3.7% formaldehyde for 24 h then placed in 30% sucrose. 
After 3 days in sucrose, brains were embedded into 15% gelatin with 4 or 3 brains per matrix. 
Blocks were frozen and sliced into 30 μm coronal sections with a sliding microtome (Shaver et 
al., 2019).  
Microglia were assessed using a chromogenic IBA-1 stain (Ito et al., 1998). Slices were 
incubated in 2% normal goat serum for 4-24 h at 4˚C then left in the IBA-1 primary antibody 
(1:2000; WAKO 019-19741) for 48 h at 4˚C. The secondary antibody was goat anti-Rabbit IgG 
(1:2000; vector BA-100) and was incubated for 90 min at 23˚C (room temperature). A 
Vectastain ABC kit (Vector Laboratories) was used following the secondary. Last, for 
visualization, 3-3’- diaminobenzidine (DAB; Vector Laboratories) peroxide solution was used 
(0.05% DAB & 0.015% H2O2 in PBS). Stains were mounted on slides, dehydrated, then cover 
slipped. Images of the brains were taken at 40x magnification using an Olympus BX43 
microscope with DP-80 13.5 megaplixel camera in CellSens software. ImageJ (NIH, Bethesda, 
MD) was used to analyze microglia count in three regions of interest: orbitofrontal cortex, 
prelimbic area, and hippocampus. Microglia cells were counted by hand and averaged across 
regions and groups. The orbitofrontal cortex (OFC) was assessed due to its involvement in the 
5CSRT, specifically important for the impulsivity aspect (Robbins, 2002). The prelimbic area 
(PrL) is also implicated in 5CSRT performance but the attentional aspect instead of impulsivity 
and was chosen for that reason (Robbins, 2002). The OFC and PrL are located near the lesion but 
remained intact which made them ideal regions to assess for interactive effects of injury, 
minocycline, and performance on 5CSRT. The hippocampus (HPC) served as the control for the 
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effects of tissue damage on inflammation since it is distal to the frontal lesion and is relatively 
unaffected by the frontal CCI injury.  
A lesion analysis was completed to assess injury size. Slices were stained with thionin 
solution to visualize lesions, so they could be measured. Thionin staining protocol consisted of 
rehydrating cells with ethanol solutions, a brief submerge in thionin solution (<20 s), and ended 
with dehydration in ethanol solutions. Immediately after the dehydration, slides were cover 
slipped. After the glue dried, images of the slides were captured using a Konica Minolta copier at 
600 DPI and then brain volume was measured using ImageJ (NIH, Bethesda, MD). Brain volume 
was calculated by averaging the area of five regions (+4.5, +3.5, +2.5, +1.5, +0.5 from bregma) 
then multiplying by thickness (5um) (Vonder Haar et al., 2017).  
Data Analysis 
For all data analysis, the MINO-Early and MINO-Late groups were analyzed separately. 
A linear regression (Injury x Drug x Week) with baseline added as a covariate was used to 
determine the effects of treatment and injury on the 5CSRT variables.  For the 5CSRT, the 
primary outcome variables were percent accuracy (correct/ (correct + incorrect)), percent 
premature responses (premature/total trials), percent omissions (omissions/total trials), and task 
efficacy index (correct/ (incorrect + premature + omissions)). Log transformations were 
performed on premature, omission, and task efficacy index to normalize data before the 
regression was completed, and an arcsine square root transformation was performed on accuracy. 
In the MINO-Late group, two regressions were completed for each variable. One regression was 
to verify the initial effect of injury (1-7 weeks post-injury) and the second to measure potential 
effects of minocycline, with week 7 post-injury serving as the baseline. Microglia were analyzed 
via IBA-1 positive cell counts and a two-way ANOVA (Injury x Drug) was completed. A two-
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way ANOVA (Injury x Drug) was used for the lesion analysis. All data analysis was completed 
using RStudio statistical software (version 4.0.2) and libraries plyr, plotrix, lmer, and lmerTest.  
Results 
 The major findings from behavioral testing and histology are provided below, but 
expanded statistics, including null findings and beta coefficients, can be found in tables (see 
Appendices). All beta coefficients were standardized.  
Early: Behavior 
 Premature. TBI increased premature responding (p = 0.001). Minocycline did not 
decrease the number of premature responses differentially in either group (p = 0.419). But, did 
have an overall effect of slope in that rats that received minocycline recovered faster compared 
to saline rats (p < 0.001; Table 2; Figure 3A).  
 Accuracy. TBI decreased accuracy (p = 0.001) and while both groups recovered over 
time, the TBI rats had a slower rate of recovery (p = 0.025; Table 3; Figure 3B). Minocycline did 
not improve accuracy in TBI rats (p = 0.854) but did lead to an overall increase in accurate 
responding over time (p = 0.023; Table 3: Figure 3B).  
 Omissions. TBI increased omissions initially (p < 0.001) but there was an overall decline 
in omissions across time (p < 0.001). Minocycline did not decrease omissions after TBI (p = 
0.558; Table 4; Figure 3C).  
Task Efficacy Index. TBI decreased the overall efficacy on the task (p = 0.001). 
Minocycline did not increase overall task performance after injury (p = 0.817) but did increase 
the rate of improvement on the task over time compared to rats that were given saline (p = 0.028; 
Table 5; Figure 3D).  


































































































Figure 3. The effects of minocycline on premature responses (A), accuracy (B), 
omissions (C), and index (D) on the 5CSRT.  TBI increased impulsivity, inattention, and 
omissions and minocycline did not recover these deficits (p = 0.001; p = 0.001; p < 0.001; p = 
0.926; p = 0.854; p = 0.558). Minocycline decreased the recovery rate of TBI and sham rats in 
premature responding and accuracy (p < 0.001; p = 0.023).  
 
Early: Histology 
 Lesion Analysis. TBI rats had smaller brain volumes and larger lesions compared to 
shams (F(1, 22) = 8.328, p = 0.009; F(1,22) = 15.705, p < 0.001) . Minocycline did not decrease 
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brain volume or lesion size ((F(1, 22) = 0.283, p = 0.600; F(1, 22) = 1.485, p = 0.236). Likewise, 
in TBI rats minocycline did not impact brain volume or lesion size (F(1, 22) = 0.042, p = 0.834; 
F(1, 22) = 0.469, p = 0.501; Figure 4).  
Figure 4. A) Brain volume and B) lesion volume. TBI decreased brain volume and 
increased lesion size (p = 0.008; p < 0.001). Minocycline did not affect post-injury brain volume 
or lesion size (p = 0.834; p = 0.501).  
Microglia. TBI did not increase number of microglia in the OFC, PrL, or HPC (F(1,22) = 
2.502, p = 0.128; F(1, 22) = 0.110, p = 0.743; F(1, 21) = 0.125, p = 0.693). In the HPC 
minocycline decreased microglia compared to vehicle rats (F(1, 21) = 13.664, p < 0.001; Figure 
5C), but this effect was not seen in the OFC or PrL (F(1, 22) = 1.139, p = 0.297; F(1, 22) = 
0.610, p = 0.443). In TBI rats, minocycline did not affect microglia levels in the OFC,  PrL, or 
HPC (F(1,22) = 0.000, p = 0.991; F(1, 22) = 2.771, p = 0.110; F(1, 21) = 0.465, p = 0.503; 
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Figure 5. Number of microglia in A) OFC B) PrL C) HPC. TBI did not increase 
microglia in the OFC, PrL, or HPC (p = 0.110; p = 0.743, p = 0.723). Minocycline did not affect 
microglia levels in the OFC or PrL (p = 0.298;  p = 0.443), but decreased microglia in the HPC 
compared to vehicle rats (p < 0.001).  
Late: Behavior 
 Premature. TBI increased impulsivity prior to the week 8 minocycline treatment (p < 
0.001; Table 2). TBI rats had a slight decline from their seven-week baseline (p = 0.027), 
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responding (p = 0.001). The late intervention of minocycline at did not attenuate impulsive 
behavior (p = 0.220; Table 2; Figure 6A).  
 Accuracy. TBI increased inattention prior to the late treatment of minocycline at 8 weeks 
post injury (p < 0.001; Table 3). Minocycline did not decrease inattention related to the TBI (p = 
0.351; Table 3; Figure 6B). There was an increase in inattention in sham rats but not minocycline 
rats after the minocycline treatment, but levels decreased across time (p = 0.022; p = 0.050; 
Table 3; Figure 6B). 
 Omissions. TBI increased omissions for the first 7 weeks post-injury (p < 0.001; Table 
4). Minocycline did not attenuate effects of omissions in TBI rats (p = 0.075; Table 4, Figure 
6C).  
 Task Efficacy Index. Overall performance on the task was decreased after TBI for the 
first 7 weeks after injury (p < 0.001; Table 5). Minocycline treatments beginning at 8 weeks 
post-injury did not improve the task efficacy (p = 0.510; Table 5; Figure 6D).  
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Figure 6. The effects of minocycline on premature responses (A), accuracy (B), 
omissions (C), and index (D) on the 5CSRT. Minocycline at 8 weeks post-injury did not 
attenuate impulsivity, inattention, omissions, or overall performance on task (p = 0.220; p = 
0.351; p = 0.075; p = 510).   
Late: Histology  
Lesion Analysis. TBI decreased brain volume and increased lesion volume when 
compared to shams (F(1,24) = 6.016, p = 0.022; F(1,24) = 9.448 p = 0.005; Figure 7A). 
Minocycline did not change brain volume or lesion volume compared to saline rats (F(1,24) = 
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minocycline in TBI rats at eight weeks post-injury (F(1, 24) = 0.499, p = 0.487; F(1, 24) = 0.002, 
p = 0.963; Figure 7).  
Figure 7. A) Brain volume and B) lesion volume. TBI decreased brain volume and 
increased lesion size (p = 0.022; p = 0.005). Minocycline did not affect post-injury brain volume 
or lesion size (p = 0.487; p = 0.963).  
 Microglia. TBI did not increase microglia levels in the OFC, PrL, or HPC (F(1,24) = 
2.041, p = 0.166; F(1,24) = 0.159, p = 0.743; F(1,23) = 0.550, p = 0.466; Figure 8). Minocycline 
did not impact the number of microglia in either the OFC or PrL (F(1,24) = 0.846, p = 0.367; 
F(1,24) = 2.395, p = 0.135). In the HPC, minocycline decreased microglia numbers compared to 
sham rats (F(1,23) = 9.89, p = 0.004; Figure 8C). Minocycline did not differentially affect 
microglia in TBI rats in the OFC, PrL, or HPC (F(1,24) = 2.771, p = 0.991; F(1,24) = 0.465, p = 
0.339; F(1,23) = 1.117, p = 0.301; Figure 8).  
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Figure 8. Number of microglia in the A) OFC B) PrL C) HPC. TBI did not increase 
microglia in the OFC, PrL, or HPC (p = 0.166; p = 0.743; p = 0.466). Number of microglia in 
the HPC was decreased in minocycline rats compared to saline rats (p = 0.004).  
Discussion 
This study examined the effectiveness of minocycline as a treatment for TBI-induced 
impulsivity and inattention at early (1-hour post-injury) and late (8 weeks post-injury) time 
points. We hypothesized that minocycline would reduce cognitive impairments for both 
treatment groups, decrease lesion size in the rats treated at the early time point, and decrease the 
number of microglia in rats treated in the early and late time points. Brain injury substantially 
Drug
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increased impulsivity and inattention, which resulted in a decrease in overall performance on the 
task (task efficacy index). The CCI model was effective in causing tissue loss in TBI rats 
compared to shams. Our histological findings indicated that microglia were not increased at 12 
weeks post-injury in the OFC, PrL, or HPC. Beyond a few subtle effects, minocycline failed to 
treat any TBI-related deficits such as impulsivity and inattention. Minocycline caused minor 
changes in behavior that progressed slowly (e.g., reduced premature responding over time; 
increased accuracy over time; increased task performance over time), but these subtle changes 
were not specific to TBI-related deficits. Additionally, minocycline did not decrease the size of 
the lesion or number of microglia in TBI rats.  
TBI-Related Changes 
Our TBI-related behavioral changes on the 5CSRT were consistent with previous studies. 
The increased impulsivity was in line with other studies done by our lab using the 5CSRT, as 
well as studies that have used alternative impulsive behavioral measures (Hehar et al., 2015; 
Martens et al., 2019; Mychasiuk et al., 2015; Vonder Haar et al., 2016). The changes in attention 
following TBI were consistent with previous work on the 5CSRT (Martens et al., 2019; Vonder 
Haar et al., 2016). Additionally, the pattern of omissions and task efficacy index was similar to 
work from previous 5CSRT studies (Martens et al., 2019; Vonder Haar et al., 2016). Together, 
these results indicate that we replicated previous studies in which severe TBI induces impulsive 
behavior and attentional impairments. In addition to behavioral changes, damage from the 
bilateral frontal CCI was consistent with what has been produced in prior work (Martens et al., 
2019; Scott & Vonder Haar, 2019; Shaver et al., 2019).  
Microglia increases after TBI are inconsistent within the literature. In this study, there 
were no increases in microglia in the OFC, PrL, or HPC 12 weeks after a severe TBI. Several 
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factors could have contributed to the differences in microglia expression after TBI, including 
injury site, the severity of the injury, or the time of tissue extraction post-injury. Previous work 
in rodent severe TBI models demonstrated increased microglia after TBI (Lam et al., 2013; 
Simon et al., 2018) These differences could be a result of varying times post-injury the tissue 
was taken. In our study, the tissue was harvested at 12 weeks post-injury. In the studies 
mentioned above, tissue was taken nine weeks post-injury, seven days post-injury, and 12 days 
post-injury (Lam et al., 2013; Simon et al., 2018). Yet, in other severe models of TBI, microglia 
levels were increased up to 12 weeks after the initial injury (Henry et al., 2020). The 
inconsistencies between this study and previous work may be due to food restriction. Rats in our 
study were maintained at 85% food restriction to ensure they were motivated to complete the 
5CSRT daily. Interestingly, food restriction alone decreases the number of microglia in rodents 
(Yegla & Foster, 2019). A 50% controlled diet suppressed levels of microglia after TBI 
compared to rats fed ad libitum (Loncareic-Vasiljkovic et al., 2012). Although this diet was more 
restricted than what our rats received, caloric restriction may contribute to the differences in our 
microglia data, as compared to previous work.  
While microglia counts may reflect some degree of pathology, microglia activation after 
TBI is one way to measure neuroinflammation. This prolonged neuroinflammatory response is 
multifaceted and other factors, such as cytokines, can also be affected. As microglia activity 
changes in the post-injury state, their characteristics and the cytokines they produce/respond to 
also change. Therefore, some characterize microglia into two states, M1-like or M2-like, to 
predict/infer cytokine activity based on microglia levels. While many people simplify microglia 
to simply M1-like or M2-like phenotypes, they can present a spectrum of pro- and anti-
inflammatory actions. Pro-inflammatory microglia are reactive with ameboid-like cell bodies, 
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thick processes, and release predominantly pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) 
chemokines, and reactive oxygen species (Kumar et al., 2016). Anti-inflammatory microglia are 
surveillant type that are ramified with smaller cell bodies and long, complex processes, and 
release anti-inflammatory factors such as TGF-β (Kumar et al., 2016). In stroke, M2-like 
microglia also release TGF-β (Hu et al., 2012). For this study, we measured microglia via cell 
count which makes it difficult to infer the type of cytokines that would have been increased or 
decreased. Future work could add an additional measure to test for cytokine levels. In previous 
work with a severe bilateral frontal injury, IL-12 was increased in the frontal cortex at 14 weeks 
post-injury, but other cytokines such as IL-6, IL-10, IL-1β, and IFN-γ were comparable to sham 
rats (Vonder Haar et al., 2016). Similarly, at 10 weeks post-injury, IL-12 was the only cytokine 
significantly increased compared to shams (Vonder Haar et al., 2017). With the same injury 
model and severity, it appears that there is no robust increase in cytokine levels at these later 
time points.  
Relative to microglia, astrocytes contribute less to the pro-inflammatory response to TBI. 
After TBI, microglia become activated and release ATP and inflammatory cytokines that drive 
astrocytes to a reactive state (Jha, Jo, Kim, & Suk, 2019; Liddelow et al., 2017). Interestingly, 
without microglia, astrocytes alone do not have a significant pro-inflammatory response. 
Exposure to lipopolysaccharide (LPS) in vitro does not prompt astrogliosis without the presence 
of activated microglia, but when microglia are primed with LPS, the astrocytes become reactive 
(Liddelow et al., 2017). Likewise, after TBI and depletion of microglia, the number of reactive 
astrocytes and pro-inflammatory markers were reduced (Witcher et al., 2018). These studies 
suggest that the neuroinflammatory response after TBI is more reliant on microglia than 
astrocytes. Regardless, astrocytes modulate microglial states by releasing factors such as 
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chemokines and cytokines, including IFN-γ (promotes pro-inflammatory microglia response) and 
TGF-β (attenuates microglial activation) (Jha et al., 2019). Thus, astrogliosis can drive both pro 
and anti-inflammatory effects after TBI, but it is likely that the sharp surge in neuroinflammation 
is modulated by microglia. For these reasons, microglia were the primary focus of this study, but 
future work could consider the role of astrocytes in the neuroinflammatory response to TBI.  
Minocycline 
 This was the first study using minocycline to treat TBI-induced impulsivity and 
inattention beginning at 8 weeks post-injury. However, treatments starting at 1-hour and 8 weeks 
post-injury failed to treat impulsivity and inattention. Our study fails to replicate some prior 
literature in which minocycline reduced cognitive deficits (Lam et al., 2013; Kovesdi et al., 
2012; Kumar et al., 2014; Sangobowale et al., 2018; Simon et al., 2018). Even studies that 
matched parameters (injury severity, age of rats, and dose) to the current study successfully 
reduced impairments, whereas the current study failed to see such differences. A possible 
explanation of this is the complexity of the behavioral tasks being used. Due to the challenging 
nature of the task, one might consider completing this task daily to be enriching for the rats. In 
fact, environmental enrichment can decrease cognitive deficits after TBI (de la Tremblaye, 
Cheng, Bondi, & Kline, 2019). Despite the possible enrichment effect gained from the 5CSRT, it 
is unlikely that enrichment can explain the failures of minocycline because of the design of this 
study. By having an early and late treatment group, the early treatment condition would have 
controlled for the potential enriching aspect of the 5CSRT because the treatment took place 
before post-injury testing. Thus, we are confident that the 5CSRT did not hinder any potential 
therapeutic effects of minocycline, and the null findings are indicative of minocycline being 
unable to treat psychiatric-like symptoms after TBI.    
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           Furthermore, minocycline reduced hippocampal-based cognitive deficits in previous 
research, but it was insufficient to decrease impulsivity and inattention. With complex behaviors 
such as the 5CSRT, it is possible that it is harder to recover from the damage since these 
behaviors are dependent on more areas of the brain. However, in previous work, we have been 
able to overcome these chronic deficits, although only transiently. Treatment with cathodal 
transcranial direct current stimulation reduced impulsivity measured by the 5CSRT after TBI 
(Martens et al., 2019). Minocycline alone does not appear to be an effective treatment for such 
cognitive deficits, but it is clear that these impairments can be treated. Transcranial direct current 
stimulation (tDCS) and minocycline have different mechanisms of action. The presumed 
mechanism of cathodal tDCS treatment are to increase dopamine levels, whereas minocycline is 
proposed to decrease neuroinflammation by reducing pro-inflammatory microglial state (Tanaka 
et al., 2013; Kobayashi et al., 2013). It is unknown whether treating dopamine dysfunction or 
neuroinflammation would be more useful to treat cognitive impairments after TBI, and more 
work is needed to determine this. Interestingly, microglia express dopamine receptors that can 
alter their activity and are upregulated after injury (Huck et al., 2015; Zhang et al., 2015). 
Specifically, dopamine receptor 2 on microglia can modulate innate immunity in microglia and 
agonism of these receptors decreases the post-stroke pro-inflammatory response (Zhang et al., 
2015). Both dopamine and neuroinflammation are dysregulated after TBI and they might be 
interacting with one another to drive cognitive deficits. Future research should explore this 
relationship to help with the development of multifaceted treatments.  
       In the current study minocycline did not affect microglia levels or lesion size, contrary to 
previous studies (Adembri et al., 2014; Haber et al., 2018; Hanlon et al., 2017; Lam et al., 2013; 
Simon et al., 2018; Vonder Haar et al., 2016). Our tissue samples were not collected until 12 
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weeks after the injury and could be the reason that we did not see similar microglia numbers as 
in previous work with minocycline treatments. At later time points post-injury, differences in 
microglia levels between TBI and sham animals are inconsistent (Arulsmay, Teng, Colton, 
Corrigan, & Collins-Praino, 2018; Henry et al., 2020). It is possible that we were less likely to 
detect a difference between minocycline and vehicle rats because by the time we collected the 
tissue, the microglia effect was no longer present. Additionally, as described above, the 
microglia levels may have been affected by the restricted diet these rats were kept on, which also 
may have added to the lack of differences. Treatment at the early time point did not reduce the 
lesion size compared to saline rats, which is inconsistent with work from the past (Adembri et 
al., 2014; Vonder Haar et al., 2014). However, parallel null findings in lesion size differences 
were reported at similar doses (Kelso et al., 2011; Kovesdi et al., 2012). In this study, to increase 
sensitivity to potentially subtle lesion effects, we measured both the volume of the brains and the 
size of the lesion. Therefore, it is likely that the null effect was a result of the ineffectiveness of 
minocycline to reduce lesion size after a severe bilateral frontal CCI.  
            Another consideration behind the ineffectiveness of minocycline could be a result of gut 
microbiome dysbiosis after TBI. The gut-brain-microbiota axis is a bidirectional communication 
system between the gut and the brain (Wang & Wang, 2016). In this system, brain dysregulation 
can affect the gut, and changes in the gut can also affect the brain. The gut can modulate brain 
activity through communication via the immune system, short-chain fatty acids, and efferent 
vagus signals. These efferent signals can affect brain neurotransmitter levels, inflammatory 
factors in the brain, and feedback on the HPA axis (Carabotti, Scirocco, Maselli, & Severi, 2015; 
Kim & Shin, 2018). Brain injury can create dysbiosis in the gut within 6 hours of the initial 
injury and persist for up to 30 days (Matharu et al., 2019). There are no studies directly linking 
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gut dysbiosis after TBI to cognitive deficits, but antibiotic use can create gut dysbiosis and 
increase cognitive impairments (Fröhlich et al., 2016). Our study used a high dose of antibiotics 
for 5 days, which may have induced further gut dysbiosis and exacerbated our cognitive 
dysfunctions. In fact, in the studies that successfully treat cognitive impairments after TBI, they 
administered minocycline once daily versus our twice daily (Kovesdi et al., 2012; Kumar et al., 
2014; Lam et al., 2013; Sangobowale et al., 2018; Simon et al., 2018). It is important to note that 
the gut dysbiosis-driven cognitive impairments were induced with a tetracycline cocktail of 
antibiotics, which may be more effective in depleting all bacteria compared to minocycline. 
Thus, it is inconclusive how minocycline effects post-injury gut dysbiosis-driven cognitive 
deficits. However, future work should consider the gut-brain axis when using minocycline or 
other antibiotics to treat post-injury dysfunction.  
Neuroinflammation and Cognitive Deficits  
 Traumatic brain injury did not increase microglia levels at 12 weeks after the injury in 
our study, and in attempting to reduce neuroinflammation, it was ineffective in treating cognitive 
deficits. In the absence of brain injury, neuroinflammation alone can increase cognitive deficits. 
Chronic administration of lipopolysaccharide (LPS) to the lateral ventricles resulted in increased 
hippocampus-based cognitive impairments (Belarbi et al., 2012). However, it is still unclear 
whether neuroinflammation could be driving complex impairments such as impulsivity, and 
based on the results of the current study, it appears it may not be enough. Despite the lack of 
difference in microglia levels at 12 weeks after the injury, impulsivity and inattention were still 
present, indicating that alternative pathways may drive these deficits.  
 Furthermore, aside from neuroinflammation being a driving factor for cognitive 
impairments after TBI, dopamine dysregulation is also a common hypothesis of the field. 
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Fascinatingly, there is evidence connecting neuroinflammation and dopamine after TBI. Limited 
work has looked at microglia and dopamine after TBI, and most evidence is corollary. An overall 
weakened DA system is associated with increased activated microglia (Huang et al., 2014). 
Increased microglia also occurred in tandem with more depletion of TH-positive cells (Acosta et 
al., 2015). Amplified pro-inflammatory cytokine, chemokine, and microglia expression was 
paired with decreased DA neurons and increased DA metabolites (Liu, Bachstetter, Cass, 
Lifshitz, & Bing, 2017). Greater amoeboid microglia are associated with increased catechol-O-
Methyl transferase, which degrades catecholamines such as DA (Redell & Dash, 2007). The pro-
inflammatory cytokine IL-1β, which is released by pro-inflammatory microglia, was related to a 
higher amount of cocaine self-stimulation, paired with decreased D1 receptor expression in the 
striatum, and increased D1 receptors in the accumbens (Vonder Haar et al., 2019). Finally, 
increased pro-inflammatory cytokines are positively related to impulsive-like behavior, which is 
indicative of dopamine deficiency (Vonder Haar et al., 2016). There is a relationship between 
microglia and dopamine after TBI, and together, they may be driving cognitive impairments. 
Additionally, the gut-brain axis plays an important role in both neuroinflammation and dopamine 
levels. Brain injury can lead to gut dysbiosis which can exacerbate TBI-related deficits. Chronic 
administration of an antibiotic cocktail decreased dopamine levels in the brain stem (O’Connor 
et al., 2019). Taken together with the results of this study, administration of minocycline could 
have worsened gut dysbiosis after TBI, and in turn, changed dopamine levels within the brain. 
The persistent impulsivity and inattention the rats in this study exhibited could have been an 
artifact of the neuroinflammation/dopaminergic interaction. Future research will consider 
studying this relationship further.   
Limitations and Future Directions 
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 A limitation of this work was the relatively unknown mechanisms of minocycline. 
Although previous work has linked the anti-inflammatory effects of minocycline by the 
inhibition of TLR4 upregulation on microglia, the mechanisms are not precise (Zhang et al., 
2015). Minocycline being ineffective to treat psychiatric-like symptoms could be due to 
mechanisms of the drug not being an adequate manipulation of microglia to reduce 
neuroinflammation. A future direction would be to use a small-molecule colony-stimulating 
factor 1 receptor (CSF1R) inhibitor, PLX5622, that can selectively and rapidly deplete microglia 
(Erblich, Zhu, Etgen, Dobrenis, & Pollard, 2011). Treatments with PLX5622 after TBI can 
deplete upwards of 90% of microglia, and after the repopulation of microglia, there is a reduction 
in pro-inflammatory markers (Henry et al., 2020). This new method of depleting and 
repopulating microglia may be more effective in treating cognitive impairments after TBI, and 
future work should consider using such methods.  
           Another limitation of this study was the quantification of microglia. By using IBA-1, we 
were only able to measure microglia via cell count instead of looking for phenotypic changes (Ito 
et al., 1998). Future work should consider an alternative approach, such as CD68, a marker of 
active macrophages or pro-inflammatory microglia (Hopperton, Mohammad, Trepanier, 
Giuliano, & Bazinet, 2018). Using IBA-1 co-stained with CD68 would allow for the 
quantification and the ability to differentiate between pro-inflammatory and anti-inflammatory 
microglia.  
 Only adult male rats were used in this study, which limits the translatability of this work. 
Although there are higher rates of TBIs amongst males, it is still important to consider both sexes 
in research (Dewan et al., 2018). After TBI, males and females have varying inflammatory and 
dopaminergic responses (Doran et al., 2019; Villapol, Loane, & Burns, 2017; Wagner et al., 
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2005). Therefore, including both males and females within a study would significantly increase 
the sample size to be able to account for sex differences. Despite the increased sample size, 
future work should consider using both males and females. Age of injury can also impact the 
post-injury response. In human populations, increased age is associated with worse functional 
outcomes after TBI (Cheng, Chi, Williams, & Thompson, 2018). This effect can also be seen in 
aged mice, as aged mice had exacerbated neuroinflammatory responses and increased motor and 
anxiety-like behaviors (Ritzel et al., 2019). Although the long-term cognitive impairments we 
examined in this study may not be as pertinent to the aging population, future work should 
address such issues.  
Conclusions 
 This work has revealed that minocycline is an ineffective treatment to reduce impulsive 
and attention deficits caused by TBI. We replicated our past TBI-related deficits of increased 
impulsivity and inattention, which increases confidence that the present minocycline findings 
were due to a null effect of the drug and not methodologic errors. Given that our minocycline 
treatment did not decrease neuroinflammation or reduce behavioral dysfunction, other therapies 
should be explored. 
  




Table 1: Five-choice serial reaction time task training stages 




Criterion to move 
on to next stage 
1 30 30 2 ≥ 30 correct trials 
2 20 20 2 ≥ 30 correct trials 
3 10 10 5 ≥ 50 correct trials 
4 5 5 5 
≥ 50 correct trials 
> 80% accuracy 
5 5 2.25 5 
≥ 50 correct trials 
> 80% accuracy 
< 20% omissions 
6 5 1.25 5 
≥ 50 correct trials 
> 80% accuracy 
< 20% omissions 
7 5 1 5 
≥ 50 correct trials 
> 80% accuracy 
< 20% omissions 
8 5 0.9 5 
≥ 50 correct trials 
> 80% accuracy 
< 20% omissions 
9 5 0.8 5 
≥ 50 correct trials 
> 80% accuracy 
< 20% omissions 
10 5 0.7 5 
≥ 50 correct trials 
> 80% accuracy 
< 20% omissions 
11 5 0.6 5 
≥ 50 correct trials 
> 80% accuracy 
< 20% omissions 
12 5 0.5 5 
≥ 50 correct trials 
> 80% accuracy 
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